Upcoming Investor Conferences for Compass Pathways
Compass Pathways plc (Nasdaq: CMPS), a biotechnology firm dedicated to improving access to transformative mental health solutions, is gearing up for a series of important investor conferences this September. These events will provide an opportunity for the company’s management to share insights into their innovative approaches in the mental health sector and to engage with both current and prospective investors.
Key Conference Details
Here are the events that Compass Pathways has scheduled for this September:
- Morgan Stanley 22nd Annual Global Healthcare Conference: Management will take part in a fireside chat on September 4, starting at 7:45 am ET, and will also hold investor meetings.
- H. C. Wainwright 26th Annual Global Investment Conference: A fireside chat is planned for September 10 at 9:30 am ET, along with additional investor meeting opportunities.
- Cantor Global Healthcare Conference: This event will feature a fireside chat on September 17 at 2:30 pm ET, and management will also host investor meetings.
Participants can access a live audio webcast of these events on the "Events" page within the Investors section of the Compass website. For those who cannot attend live, a replay of each webcast will be available for 30 days following the events.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is committed to enhancing the lives of individuals facing mental health challenges that are not adequately addressed by existing treatments. The company is at the forefront of developing a new model of psilocybin treatment through its proprietary formulation known as COMP360. This groundbreaking treatment combines the administration of synthetic psilocybin with essential psychological support, showcasing the potential to transform mental health care.
Innovative Treatments and Clinical Programs
COMP360 has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has also been granted Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). These recognitions highlight the significance and promise of the approaches taken by Compass Pathways.
Currently, the company is conducting a pivotal phase 3 clinical program, which represents the largest randomized, controlled, double-blind psilocybin treatment study ever undertaken, specifically targeting TRD. Prior to this, Compass Pathways successfully completed a phase 2b study that demonstrated a statistically significant and clinically meaningful reduction in depressive symptoms after just three weeks among participants who received a single dose of 25mg of COMP360 along with psychological support.
Additionally, Compass Pathways has wrapped up an open-label phase 2 study focusing on COMP360 for post-traumatic stress disorder (PTSD) and is now progressing with a phase 2 study aimed at treating anorexia nervosa. The extensive range of ongoing research underscores the company’s dedication to tackling various mental health issues through innovative treatment solutions.
Corporate Presence and Vision
With its headquarters in London, Compass Pathways also maintains offices in New York and San Francisco, reinforcing its commitment to key markets. The company’s overarching vision is to create a world where mental wellbeing is prioritized, aiming to empower individuals who face mental health challenges.
Investor Communication Strategy
Compass Pathways actively engages with investors and the public through multiple channels. Their main website, investor relations site, and social media platforms serve as key resources. The company regularly shares updates, including investor presentations, SEC filings, and press releases, to keep stakeholders informed about its operations and advancements in treatment methodologies.
For inquiries or additional information, interested parties can contact:
Media Contact: Sally Bain, media@compasspathways.com, +1 781 458 0443
Investor Contact: Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324
Frequently Asked Questions
What is Compass Pathways plc known for?
Compass Pathways plc is recognized for its innovative strategies in treating mental health disorders, particularly its development of psilocybin treatments.
Where will the upcoming conferences take place?
The upcoming investor conferences will be available through live audio webcasts on the Compass Pathways website.
What is COMP360?
COMP360 is Compass Pathways’ proprietary formulation of synthetic psilocybin, utilized alongside psychological support to treat mental health disorders.
What designations has COMP360 received?
COMP360 has been awarded Breakthrough Therapy designation by the FDA and Innovative Licensing and Access Pathway designation in the UK.
How can I stay updated about Compass Pathways?
You can stay informed by visiting the company’s website, checking their investor relations page, and following their social media channels for the latest news and updates.
